Merck KGaA Sponsored ADR (MKKGY)
OTHER OTC:MKKGY
MKKGY Stock Chart & Stats
$29.80
--
Market closed
$29.80
--
Day’s Range― - ―
52-Week Range$23.82 - $30.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)19.41K
Market Cap
$57.93B
Enterprise Value$59.90B
Total Cash (Recent Filing)$2.74B
Total Debt (Recent Filing)$11.96B
Price to Earnings (P/E)42.0
Beta0.64
Next Earnings
May 14, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend Yield1.77%
Share Statistics
EPS (TTM)0.43
Shares Outstanding646,211,240
10 Day Avg. Volume0
30 Day Avg. Volume19,407
Financial Highlights & Ratios
PEG Ratio-2.05
Price to Book (P/B)1.86
Price to Sales (P/S)2.62
P/FCF Ratio23.53
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue2.85
Enterprise Value/Gross Profit4.86
Enterprise Value/Ebitda9.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.78
Revenue Forecast (FY)$24.10B
Bulls Say, Bears Say
Bulls Say
Diversified, Recurring Revenue StreamsMerck KGaA’s three-segment model (Life Science, Healthcare, Electronics) creates multiple, partly uncorrelated revenue streams and recurring consumables demand in bioprocessing and labs. This structural diversification smooths cash flow cycles and reduces reliance on any single product or market over months to years.
Solid Free Cash Flow GenerationDependable free cash flow, including a rebound in 2024 and further growth in 2025, provides durable internal funding for capex, M&A and dividends. Sustained FCF supports strategic investments (sites, megasites) and shareholder return while cushioning cyclical EBITDA swings across segments.
Semiconductor Materials Strength & CapexStrength in semiconductor materials taps a secular AI/advanced-node tailwind; the EUR 500m Taiwan megasite and ongoing site investments enhance scale and customer proximity. These structural investments improve competitive positioning in high-margin specialty materials over multi-year equipment and node cycles.
Bears Say
Choppy Revenue And Profit Step-downIntermittent top-line performance and a recent step-down in net income reduce visibility and make margin maintenance harder over time. Without stable organic revenue growth, sustaining mid‑teens margins and funding ongoing R&D and capex becomes more challenging, increasing execution risk in the medium term.
Rising Leverage In 2025Higher debt alongside declining equity in 2025 weakens financial flexibility. Elevated leverage raises interest and refinancing risk, reduces headroom for opportunistic M&A or downside absorbency, and limits capacity to cushion profit volatility or fund aggressive capex without further balance-sheet actions.
Product Lifecycle And FX ExposureAssumed loss of U.S. Mavenclad exclusivity (material sales share) creates a structural revenue gap in Healthcare that requires new launches or M&A to replace. Persistent adverse and volatile FX can depress reported sales and margins, complicating medium-term planning and organic growth targets.
Merck KGaA Sponsored ADR News
MKKGY FAQ
What was Merck KGaA Sponsored ADR’s price range in the past 12 months?
Merck KGaA Sponsored ADR lowest stock price was $23.82 and its highest was $30.70 in the past 12 months.
What is Merck KGaA Sponsored ADR’s market cap?
Merck KGaA Sponsored ADR’s market cap is $57.93B.
When is Merck KGaA Sponsored ADR’s upcoming earnings report date?
Merck KGaA Sponsored ADR’s upcoming earnings report date is May 14, 2026 which is in 29 days.
How were Merck KGaA Sponsored ADR’s earnings last quarter?
Merck KGaA Sponsored ADR released its earnings results on Mar 05, 2026. The company reported $0.435 earnings per share for the quarter, missing the consensus estimate of $0.459 by -$0.024.
Is Merck KGaA Sponsored ADR overvalued?
According to Wall Street analysts Merck KGaA Sponsored ADR’s price is currently Overvalued.
Does Merck KGaA Sponsored ADR pay dividends?
Merck KGaA Sponsored ADR pays a Annually dividend of $0.5 which represents an annual dividend yield of 1.77%. See more information on Merck KGaA Sponsored ADR dividends here
What is Merck KGaA Sponsored ADR’s EPS estimate?
Merck KGaA Sponsored ADR’s EPS estimate is 0.46.
How many shares outstanding does Merck KGaA Sponsored ADR have?
Merck KGaA Sponsored ADR has 646,211,240 shares outstanding.
What happened to Merck KGaA Sponsored ADR’s price movement after its last earnings report?
Merck KGaA Sponsored ADR reported an EPS of $0.435 in its last earnings report, missing expectations of $0.459. Following the earnings report the stock price went down -8.459%.
Which hedge fund is a major shareholder of Merck KGaA Sponsored ADR?
Currently, no hedge funds are holding shares in MKKGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.59%
12-Months-Change
Fundamentals
Return on Equity
9.02%
Trailing 12-Months
Asset Growth
13.43%
Trailing 12-Months
Company Description
Merck KGaA Sponsored ADR
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
MKKGY Company Deck
MKKGY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but resilient picture: Merck delivered on 2025 guidance, achieved organic EBITDA growth, and showed sector-level recoveries (notably Life Science and semiconductor materials) and strategic progress through M&A and site investments. However, meaningful headwinds remain — significant foreign exchange pressures, the imminent U.S. loss of Mavenclad exclusivity, near-term weakness in the Electronics DS&S business, and regulatory/portfolio uncertainties. Management’s proactive strategic moves and solid cash generation balance these risks, leaving the company positioned for medium-term growth but with clear short-term challenges.View all MKKGY earnings summariesTechnical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Haleon PLC Sponsored ADR
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---